đ â Kim, et al.
The goal of the present study was to identify potential pivotal molecules with implications for novel and efficacious treatment options for pancreatic cancer, a disease with limited treatments available and notorious for its aggressive nature.
Full text is available đ
Pancreatic cancer is one of the most aggressive forms of cancer and is the seventh leading cause of cancer deaths worldwide. Pancreatic ductal adenocarcinoma (PDAC) accounts for over 90% of pancreatic cancers. Most pancreatic cancers are recalcitrant to radiation, chemotherapy, and immunotherapy, highlighting the urgent need for novel treatment options for this deadly disease. To this end, we screened a library of kinase inhibitors in the PDAC cell lines PANC-1 and BxPC-3 and identified two highly potent molecules: Aurora kinase inhibitor AT 9,283 (AT) and EGFR kinase inhibitor WZ 3,146 (WZ). Both AT and WZ exhibited a dose-dependent inhibition of viability in both cell lines.